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Intercellular Adhesion Molecule-1 Is Upregulated in
Ischemic Muscle, Which Mediates Trafficking of
Endothelial Progenitor Cells
Chang-Hwan Yoon, Jin Hur, Il-Young Oh, Kyung-Woo Park, Tae-Youn Kim, Jae-Hoon Shin,
Ji-Hyun Kim, Choon-Soo Lee, June-Key Chung, Young-Bae Park, Hyo-Soo Kim
Background—Trafficking of transplanted endothelial progenitor cells (EPCs) to an ischemic organ is a critical step in
neovascularization. This study was performed to elucidate the molecular mechanism of EPC trafficking in terms of
adhesion molecules.
Methods and Results—Using murine hindlimb ischemia model, we examined expressions of E-selectin, intercellular
adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and platelet-endothelial cell adhesion
molecule-1 (PECAM-1) in ischemic muscle by immunofluorescence. ICAM-1 was overexpressed in ischemic muscle
compared with nonischemic muscle, whereas expressions of E-selectin, VCAM-1, and PECAM-1 did not show that
much difference. ICAM-1 was also upregulated by hypoxia in murine endothelial cells (ECs) as assessed by immunoblot
and flow cytometry. EPCs were attached to ECs specifically through ICAM-1/-2 integrin interaction in vitro. When
EPCs were labeled with fluorescent dye or radioisotope (Tc-99m-HMPAO) and systemically administrated in vivo,
EPCs preferentially homed to ischemic muscle. By blocking ICAM-1, EPCs entrapment to ischemic limb in vivo was
significantly reduced and neovascularization induced by EPC transplantation was attenuated.
Conclusions—ICAM-1 is upregulated by ischemia, and this is closely associated with EPCs entrapment to ischemic limb.
Our findings suggest that ICAM-1 expression might be important in regulating the process of neovascularization
through its ability to recruit EPCs. (Arterioscler Thromb Vasc Biol. 2006;26:1066-1072.)
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Neovascularization is a physiological response to ische-mia that often produces insufficient collateral vessels to
resolve its symptoms or signs.1 In ischemic heart disease,
therapeutic angiogenesis leading to enhanced collateral ves-
sels may be an ideal physiological therapeutic modality.2 At
present, many trials with stem cells or endothelial progenitor
cells have been conducted or are undergoing investigation to
test this theory.3–6
Because the number of circulating endothelial progenitor
cells (EPCs) may limit the ultimate magnitude of therapeutic
angiogenesis, strategies based on administering ex vivo
expanded populations of EPCs, harvested from the patient’s
circulating blood, appear promising.3–5 However, increased
recruitment and specific lodging of EPCs into ischemic
tissues may be another target. We may be able to increase the
efficiency of therapeutic angiogenesis if we could enhance
selective lodgment, or “homing,” of EPCs to the recipient’s
ischemic organ.
Recently, several molecules have been reported to be
related with the homing process.7–10 However, these are not
molecules that have been confirmed to be expressed in the
ischemic tissue but rather investigational molecules, locally
injected to the tissues,7,8 or those expressed in tumors.10 To
maximize the homing of EPCs to the ischemic tissue, we need
to elucidate the key molecules that take part in the physio-
logical or pathologic process after ischemia. Therefore, we
investigated the change in expression of adhesion molecules
in endothelial cells after ischemia, and whether these mole-
cules are involved in the homing of EPCs to ischemic tissue.
Materials and Methods
The basic design of the study was to: (1) identify a probable adhesion
molecule for the homing of EPCs to ischemic tissues; (2) confirm the
interaction of EPCs and endothelial cells through ICAM-1 in vitro
adhesion assay; and (3) test whether the expression of intercellular
adhesion molecule-1 (ICAM-1) is essential for EPC homing in a
hindlimb ischemia model by using monoclonal neutralizing antibody
against ICAM-1.
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Mouse Hindlimb Ischemia Model
All procedures were approved by the Institutional Review Board of
Seoul National University and were performed in accordance with
the Institutional Animal Care & Use Committee of Seoul National
University Hospital. Six-week-old C57BL6/J mice (Biogenomics,
Korea) were used for all animal experiments. Mice were anesthetized
with 50 mg/kg intraperitoneal pentobarbital. To induce muscle
ischemia, a unilateral femoral artery was removed as previously
described.11,12
Tissue Preparation and Immunofluorescence
One day after unilateral femoral artery excision, mice were eutha-
nized by administering an overdose of sodium pentobarbital. The
calf muscle and tibial bone of either an ischemic hindlimb or a
nonischemic one were rinsed in phosphate-buffered saline (PBS) to
remove excess blood, snap-frozen in liquid nitrogen (LN2), and
stored at 80°C.
Ten-micrometer-thick histological sections were prepared from
snap-frozen tissue samples. Immunofluorescent staining of adhesion
molecules was performed using the following antibodies: for
ICAM-1 or vascular cell adhesion molecule (VCAM-1), rat mono-
clonal antibodies against mouse ICAM-1 or VCAM-1 (R&D sys-
tem); fluorescein isothiocyanate (FITC)-conjugated rabbit anti-rat
immunoglobulin as secondary antibody (DAKO); for E-selectin,
goat polyclonal antibody against murine E-selectin (Santa Cruz
technology); rat anti-goat immunoglobulin as secondary antibody
(DAKO); and for platelet-endothelial cell adhesion molecule-1
(PECAM-1), FITC-labeled PECAM-1 (DAKO).
Western Blot of ICAM-1
Please see http://atvb.ahajournals.org for more information.
Fluorescence-Activated Cell Sorting
Please see http://atvb.ahajournals.org for more information.
Mouse Bone Marrow Harvesting and EPC Culture
Please see http://atvb.ahajournals.org for more information.
Adhesion Studies In Vitro
Cultured EPCs, fibroblasts (negative control) and Jurkat, and leuke-
mic T-lymphocytes (positive control) were labeled with DiI, and
then 105 cells per well were incubated on VEGF-stimulated (50
ng/mL) MS-1 (murine endothelial cells, ATCC) monolayers in
HBSS supplemented with 2 mmol/L calcium and magnesium in the
presence of ICAM-1 blocking monoclonal antibody (10 g/mL;
R&D Systems, Minneapolis, Minn) or isotype control antibody (10
g/mL) for 1 hour. After removing nonadherent cells, the number of
DiI-labeled cells bound to the endothelium was quantified under
fluorescent microscopy.
EPC Injection
One day after unilateral femoral artery excision, 1106 cultivated
EPCs in 100 L EBM-2 media without growth factors were
administered systemically by cardiac puncture using an insulin
syringe with 27-guage needle. EPCs were tagged with either fluo-
rescent carbocyanine DiI dye (Molecular Probes) or Tc-99m hexa-
methylpropyleneamine oxime (HMPAO) for tracking and quantifi-
cation as explained later. For the blocking of ICAM-1/2-integrin
interaction, 10 g of ICAM-1 monoclonal antibody (R&D Systems,
Minneapolis, Minn) was administered to the ischemic mice 30
minutes before cell transplantation and EPCs were also incubated
with the monoclonal antibody to 2-integrin (5 g/mL; Santa Cruz
Biotechnology), the ligand of ICAM-1 for 30 minutes before
injection. Isotype antibody (rat IgG2A; R&D Systems) was used as a
control with the same dose and concentration.
Quantification of EPC Homing
To quantify the homing of EPCs to the ischemic organ, we used 2
methods. One was direct counting of DiI-labeled EPCs in the
histological section of each organ, which were harvested 15 hours
after transplantation. The other was measuring specific radioactivity
per gram of tissue of each organ after transplantation of radiolabeled
EPCs. Before cellular transplantation, EPCs in suspension were
washed with PBS and incubated with DiI at a concentration of 2.5
g/mL in serum-free basal medium for 10 minutes at 37°C or with
Tc-99m HMPAO at a concentration of 1mCi per 1107 EPCs for 30
minutes. After PBS washes, the cells were resuspended in EBM-2
medium. Cell labeling and quantitation using Tc-99m HMPAO is a
well-established method that showed stable labeling over 15 hours
and 1% covariance when measured over 10 000 cpm.13 Further-
more, when we reattached and cultured the labeled cells, they
showed as good survival and proliferation as unlabeled control EPCs
(data not shown).
Harvested organs were weighed, and radioactivity was measured
using a gamma counter after correcting for radioactive decay. To
compensate for different muscle volumes, we compared radioactivity
per milligram of tissue. For the direct counting of homed cells in the
hindlimb, the middle belly of the thigh muscles were sectioned at
200-m intervals. DiI positive cells were counted in each section by
a fluorescent microscopy. Total cell number was divided by total
muscle area, which was measured using Image-Pro Plus
(MediaCybernetics).
Capillary Density and Laser Doppler
Perfusion Analysis
For evaluation of the ICAM-1 blocking on therapeutic neovasculo-
genesis using EPCs, laser Doppler perfusion image analyzer (Moor
Instrument, Wilmington, De) was used to record serial blood flow
measurements of both blocking and nonblocking groups (n12,
respectively) over the course of 3 weeks after operation as was
described in our previous study.12 Medium was also administered
into another control group of mice to compare the effect of EPC
transplantation. Capillary density in the ischemic muscle of the 3
groups was also measured by PECAM-1 immunofluorescent
staining.
Statistical Analysis
Data are expressed as meanSEM. The unpaired 2-tailed t test was
used to compare continuous variables. Perfusion data were analyzed
by repeated measure AVOVA with Tukey post hoc multiple analy-
sis. All calculations were performed using SPSS 11.0, and P0.05
was considered statistically significant.
Results
Ischemia Results in Overexpression of ICAM-1 on
the Endothelial Cells In Vivo and In Vitro
In a model of unilateral hindlimb ischemia, immunofluores-
cence examinations of nonischemic and ischemic muscle
showed different patterns of ICAM-1, VCAM-1, E-selectin,
and PECAM-1 expression. In ischemic muscles, there was a
significantly increased expression of ICAM-1 on ECs of
small to medium sized vessels (Figure 1a) and capillaries
(Figure 1b) compared with nonischemic muscles (Figure 1c,
1d). Bone marrow and spleen were stained as positive
controls (Figure 1e, 1f). In contrast, VCAM-1 expression was
observed on the vessel wall in the ischemic muscle (Figure
1g, 1h), which was not different from that in the nonischemic
muscle (Figure 1i, 1j). VCAM-1 expression in the bone
marrow and spleen was similar to ICAM-1 expression (Fig-
ure 1k, 1l). E-selectin was only scantly expressed on small to
medium sized vessels in ischemic muscles (Figure 1m) and
not found on the capillaries (Figure 1n), which were similar to
the findings in nonischemic muscles (Figure 1o, 1p). Bone
marrow and spleen, positive controls, showed high expres-
sion of E-selectin (Figure 1q, 1r). Although the expression of
PECAM-1 was diffusely distributed on the endothelial cells
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of vasculatures, it was not changed by ischemia (Figure 1s, 1t,
1u, 1v). Bone marrow and spleen were stained not only on the
vessel wall but also on the cellular component of the tissue.
(Figure 1w, 1x).
To confirm in vitro that ischemia upregulates expression of
ICAM-1 on ECs, we exposed ECs to hypoxia and measured
the changes in ICAM-1. On exposure to hypoxia, endothelial
cells showed a significant upregulation of ICAM-1 protein
expression compared with those in normoxic condition as
shown by immunoblot assay (Figure 2a). The upregulation of
ICAM-1 on the surface of ECs in response to hypoxia was
also confirmed by FACS analysis (Figure 2b).
Bone Marrow-Derived EPCs Express 2-Integrin,
the Ligand of ICAM-1
As we cultured the bone marrow mononuclear cells
(BMMNC) in an EPC-culture condition for 7 days, they
became spindle shaped and showed phenotypes such as BS-1
lectin binding and DiI-acLDL uptake (Figure 3a). They also
expressed Flt-1, Flk-1, and von Willebrand factor (Figure 3b),
which are characteristics of EPCs, whereas fibroblasts and
undifferentiated BMMNCs, used as negative control, did not
express these markers. These cultured cells were used as
EPCs for the experiments.
Both BMMNCs and EPCs showed the expression of
2-integrin, a ligand of ICAM-1 (Figure 3c), which means
these cells possess the potential to attach to endothelial cells
through interaction between ICAM-1 and 2-integrin. Posi-
tive control, Jurkats, and negative control, fibroblasts, were
also demonstrated.
Blocking ICAM-1 Results in Significant Reduction
of EPC Adhesion to Endothelial Cells In Vitro
To demonstrate that ICAM-1 plays a critical function in the
adhesion of EPCs, we performed an in vitro adhesion assay
with or without monoclonal blocking antibody against
ICAM-1. The attachment between EPCs and MS-1 was
significantly reduced by pretreatment with blocking antibody
to ICAM-1 (number of attached EPCs on MS-1 monolayer:
192.4/mm2 versus 9.62.9/mm2 for nonblocked versus
blocked, P0.001) (Figure 4a to 4c). In comparison to EPCs,
fibroblasts (negative control) did not attach to the endothelial
Figure 1. Differential expression of adhesion molecules in the
ischemic or nonischemic muscle compared with bone marrow
and spleen (a to f). ICAM-1 immunofluorescent staining: ICAM-1
was overexpressed in both of arteries (a) and capillaries (b) in
the ischemic muscle (isch m.). Nonischemic muscle (non-isch
m.) did not show these changes in both vessels (c, d). Bone
marrow (BM) and spleen tissues (e,f) were used for positive con-
trols. VCAM-1 immunofluorescent staining (g to l). VCAM-1 was
expressed in both of arteries (g) and capillaries (h) in the ische-
mic muscle as was in the nonischemic muscle (i, j). Positive
controls, bone marrow and spleen (k.l). E-selectin immunofluo-
rescent staining (m to r). E-selectin was slightly expressed on
arteries (m) but not on capillaries (n). E-selectin was not
expressed on the vessels of nonischemic muscle (o, p). Positive
controls, bone marrow, and spleen (q,r). PECAM-1 immunofluo-
rescent staining (s to x). PECAM-1 was ubiquitously expressed
on all vessels, irrespective of vessel type or ischemia.
Figure 2. Hypoxia induced ICAM-1 expression on endothelial
cells. Twenty-four-hour hypoxia significantly increased ICAM-1
expression of murine endothelial cells (a). Such increase of
ICAM-1 was also demonstrated by FACS analysis (b). Black
lines are isotype control and gray lines are anti-ICAM-1.
Figure 3. Bone marrow-derived cultured endothelial progenitor
cells (EPC) expressed the counter-ligand of ICAM-1, 2-integrin.
Bone marrow-derived murine EPCs (a) (LM; light microscopic
figure) were cultured for 7 days and characterized with FITC-
labeled BS-1 lectin (green) binding and by DiI-acLDL (red)
uptake. On day 7, cultured EPCs (b) expressed Flt-1, Flk-1, and
von Willebrand factor (vWF), which was absent or very weak in
negative control, fibroblast (NIH-3T3), or bone marrow mononu-
clear cells. FACS analysis (c) confirmed the expression of
2-integrin on the cell surface of both bone marrow mononu-
clear cells and cultured EPCs. Positive control, murine T lym-
phocytes (Jurkat), and negative control, fibroblast, were also
demonstrated.
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monolayer whereas Jurkat cells (positive control) showed a
large amount of attachment to endothelial cells, which was
also attenuated by ICAM-1 blocking (Figure 4c).
ICAM-1 Plays an Important Role in EPC Homing
and Neovasculogenesis in Ischemic Hindlimb
Muscles In Vivo
Next, we examined whether the blocking of ICAM-1 reduced
EPC homing to ischemic limb in vivo. Scintigrams 2 hours
and 15 hours after systemic administration of radiolabeled
EPCs showed that most of the administered EPCs homed to
spleen and bone marrow (Figure 5a, 5b). These scintigrams
are not appropriate for quantification. Therefore, we mea-
sured the radioactivity of the removed tissues using a gamma
counter after euthanizing the mice at 15 hours after adminis-
tration. We could confirm the substantial homing of EPCs to
bone marrow and spleen quantitatively with this method
(Figure 5c). At 2 hours after administration, there was no
difference between the nonblocking group and blocking
groups (Figure 5a, 5b). However, at 15 hours after adminis-
tration, the nonblocking group showed slightly higher radio-
activity in the ischemic limb than in the blocking group on the
image (Figure 5a, 5b) as well as on the quantitative data
(Figure 5d, gray bars). The radioactivity of the nonischemic
muscles was not changed by blocking ICAM-1, whereas the
radioactivity of the ischemic muscle was significantly re-
duced by blocking ICAM-1 (Figure 5d).
We confirmed that injected EPCs homed to the ischemic
limbs and incorporated into capillaries 15 hours after sys-
temic administration. DiI-labeled (red) EPCs selectively
homed to the capillary spaces of the ischemic limb in contrast
to the nonischemic limb (Figure 6a, 6b). The number of
trafficked EPCs in the ischemic limb was significantly
decreased by treatment of ICAM-1 neutralizing antibody
(Figure 6c), suggesting that ICAM-1 expression plays an
important role in the trafficking of EPCs to the ischemic
hindlimb. The numbers of EPCs per unit area were demon-
strated in Figure 6d.
The perfusion ratio of the ischemic limb to the nonische-
mic limb was significantly decreased by blocking ICAM-1 at
postoperative days 14 and 21 (Figure 6e). Capillary density of
the ischemic muscle at postoperative day 21 was also signif-
icantly reduced by blocking ICAM-1 (Figure 6f), which
suggested that decreased EPC homing by blocking ICAM-1
resulted in decreased neovasculogenesis in the ischemic
muscle.
Figure 4. In vitro adhesion assay showed that ICAM-1 is impor-
tant for attachment of EPCs to endothelial monolayer. A repre-
sentative figure (a) shows that DiI-labeled EPCs attached to en-
dothelial monolayer without ICAM-1 blocking antibody. ICAM-1
blocking antibody (b) significantly reduced the number of
attached EPCs to the monolayer. Negative control, fibroblast, (c)
did not adhere to the monolayer as many as EPCs. EPCs adhe-
sion to endothelial layer was similar to the positive control,
murine T lymphocytes (Jurkat), where ICAM-1/2-integrin inter-
action was necessary for the adhesion.
Figure 5. ICAM-1 blocking in vivo reduced the entrapment of
radiolabeled EPCs in the ischemic muscle. Scintigrams 2 hours
after systemic administration (a,b) of radiolabeled EPCs did not
show any difference of the homing to ischemic limb between the
nonblocking group and blocking one. However, at 15 hours
after administration, the nonblocking group showed slightly
higher radioactivity in the ischemic limb than the blocking group
on the image. The difference, however, was so small that we
could not compare them using the images. Therefore, quantifi-
cation of the cells (c) that homed to the muscles was performed
by gamma counter after removing the muscles. To compensate
for different tissue volumes, we compared radioactivities per
milligram of tissue. The distribution of administered EPCs was
greatest in spleen and bone marrow, whereas it was little in
muscles. But the distribution to ischemic muscle was greater
than nonischemic muscles. The radioactivity of the nonischemic
muscles (d) was not changed by blocking ICAM-1, whereas the
radioactivity of the ischemic muscle was significantly reduced
by blocking ICAM-1.
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Discussion
In this study, to investigate the molecular mechanism of EPC
homing to ischemic limb, we found that ischemia in muscle
tissue significantly and selectively increased expression of
ICAM-1. Furthermore, we showed that bone marrow-derived
EPCs expressed 2-integrins, the ligand of ICAM-1, suggest-
ing that ICAM-1/2-integrin binding plays a role in homing
of EPCs to ischemic muscle tissue. The importance of
ICAM-1 was confirmed by using a blocking antibody for
ICAM-1, which significantly decreased both adhesion of
EPCs to endothelial cells in vitro and homing of EPCs to
ischemic limb in vivo.
When we evaluated the distribution of the EPCs that we
introduced systemically in the animals, the majority of the
transplanted EPCs were found in the spleen or the bone
marrow, which was also demonstrated by another group.14
These results confirmed our preliminary thoughts that the
mere mobilization or transplantation of EPCs cannot guaran-
tee its incorporation in ischemic tissues. Several groups have
previously reported similar observations and suggested that
an adjunctive method is necessary to increase the efficiency
of cell therapy.7–9,15,16 The elucidation of the molecular
mechanism of homing may give the answer to such questions.
Multi-Step Process of EPC Homing
In the light of the results up to now, EPC homing may involve
multistep process. Certain factors (eg, VEGF,17 G-colony
stimulating factor,6,18 SDF-1,19 and MCP-120) in the blood
mobilize and enhance differentiation of stem cells toward the
EPC lineage. At the same time, several mechanisms are
activated at the tissue site requiring neovasculogenesis, which
increase chemoattractant molecules and endothelial adhesion
molecules so that EPCs can bind and transmigrate through the
vascular wall into the interstitial tissue. EPCs, after homing to
these tissues, form clusters contributing to neovasculogen-
esis.10 Among these steps, the adhesion and transmigration is
the key step for local accumulation of EPCs at the ischemic
site. Consequently, SDF-1, VEGF, and MCP-1 have been
investigated and reported as local chemoattractant factors,
which can possibly increase the selective lodgment of EPCs
when they are locally injected.17,19,20 However, the role of
adhesion molecules has not been clearly elucidated for
homing of EPCs, especially in the ischemic site.
Adhesion Molecules
There are a lot of adhesion molecules that can be expressed
on the endothelium and each of them plays its own role in the
attachment of blood cells as follows: E- and P-selectins for
initial rolling; Integrin, ICAM-1, and VCAM-1 for firm
adhesion; and ICAM-1 and PECAM-1 for transmigration.21
In this study, we found that in response to ischemia, ICAM-1
was selectively overexpressed in the ischemic muscle com-
pared with the nonischemic muscle. We also observed that
blocking ICAM-1 significantly reduced homing of EPCs to
the ischemic muscle.
Recently, E- and P-selectin have been shown to play
important roles in the trafficking of the embryonic EPCs
during tumor angiogenesis.10 Yet it is important to underscore
that this work was performed with embryonic EPCs and a
tumor model, whereas we used adult EPCs and a murine
hindlimb ischemia model. It is likely that different cell types
and different organ types may use distinct mechanisms for
homing of EPCs. In the present study, we also found that
bone marrow and spleen entrapped most of the transplanted
EPCs probably caused by the high expression of E-selectin as
well as ICAM-1. It is well-established that interactions of
selectins with selectin-ligands mediate the rolling of cells on
the surface of endothelial cells as the initial step of homing.22
Based on our observation, relatively low expression of
E-selectin in the ischemic limb might result in the low rate of
EPC incorporation into the hindlimb compared with the bone
marrow and spleen and, at the same time, make ICAM-1
essential for homing of EPCs to the ischemic hindlimb.
Further studies are needed to elucidate a potentially syner-
gistic role of other adhesion molecules and their counterli-
gands for the multi-step recruitment process of adult endo-
thelial progenitor and stem cells to ischemic tissue.
PECAM-1 has a role in transmigration rather than attach-
ment.21 More importantly, PECAM-1 expression did not
change in response to ischemia in the present study. There-
fore, although PECAM-1 may participate in the multi-step
process, it does not seem to be an essential molecule for the
preferential homing of EPCs to ischemic tissue.
Figure 6. Immunofluorescent staining showed that EPCs were
preferentially entrapped in the ischemic muscle through ICAM-1.
DiI-labeled human EPCs (a) (red) were trafficked in the BS-1
lectin-stained capillaries (green) of the ischemic hind-limb of
nude mouse. In the nonischemic muscle (b), there was no EPC
observed. After pretreatment of ICAM-1–blocking monoclonal
antibody (c), the number of homed EPCs to the ischemic mus-
cle significantly reduced. Compared with the nonblocking group
(d), the blocking group showed less EPCs in the ischemic mus-
cle. Serial measurement of the perfusion by laser Doppler image
analysis (e) showed that blocking ICAM-1 significantly attenu-
ated the enhanced recovery of perfusion in the ischemic limb by
EPC transplantation. (n12, †P0.05; ‡P0.01). Capillary den-
sity (f) in the ischemic muscle was also decreased by blocking
ICAM-1.
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ICAM-1 has been shown to induce the firm attachment of
the rolling cells and facilitate angiogenesis.21,23–25 Its expres-
sion was under control of VEGF, Akt, and nitric oxide, which
are closely related with angiogenesis.26 Recently, Dimmeler
et al showed that 2-integrin, counter-ligand of ICAM-1, on
EPCs was related to homing of EPCs.9 Their data support that
ICAM-1 overexpression in the ischemic muscle, may be the
key molecular change to induce preferential recruitment of
EPCs into the site.
ICAM-1: Inflammation Versus Angiogenesis and
Physiological Versus Pathologic Role of ICAM-1
in Ischemia
ICAM-1 has been known to be an adhesion molecule for
recruiting leukocytes, lymphocytes, neutrophils, monocytes,
etc, to increase inflammatory response to the sites.27 There-
fore, overexpression of ICAM-1 may recruit leukocytes to the
ischemic muscle and then enhance pathologic or hazardous
effects as described in several previous reports.28–30 How-
ever, inflammation always accompanies angiogenesis.1 Re-
cruited monocytes/macrophages or lymphocytes were re-
ported to enhance angiogenesis and collateral growth in the
ischemic organ.31,32 In this regard, ICAM-1 overexpression
may be the key coordinator to organize inflammation and
angiogenesis in the ischemic organ through recruiting inflam-
matory cells and EPCs. It is likely that the net result in the
ischemic organ may lie anywhere on a spectrum from
physiological responses to pathologic changes depending on
which kinds of cells are dominant in that process. If EPCs are
sufficient and its function is good, more angiogenesis would
be expected with aid of inflammatory cells. Further studies
are warranted to better understand this issue.
Radioisotope in Small Animal Study
The quantification of cell lodging is a prerequisite for any
analysis of the homing mechanism, especially in vivo. How-
ever, counting cells in tissue is too time-consuming and
laborious to be used for assessing distribution of EPCs to
various organs after systemic administration. Therefore, we
used an easier, relatively straightforward method, Tc-99m
HMPAO labeling and quantification of EPC homing by
gamma counter. A recent report supported the use of this
method for demonstrating the distribution of transplanted
human EPCs in a nude rat acute myocardial infarction model
and showed the selective accumulation of cells in the ische-
mic heart.14 In the present study, we found a good correlation
between counting cells and measuring radioactivity and used
these methods to investigate the homing mechanism. Radio-
isotope imaging was qualitatively used to see the distribution
of transplanted EPCs in the mice. However, it was not
appropriated for quantitative analysis because low signal and
low image resolution because of the small size of a mouse.
We observed small number of EPCs in the nonischemic
muscle as shown in Figures 5c and 6d. It is possible that some
EPCs were physically entrapped in the vascular lumen
because of the relatively large size of the transplanted EPCs.
Vajkoczy et al showed similar results in their recent article
using intravital fluorescent videomicroscopy.10
In conclusion, ICAM-1 is significantly upregulated in the
ischemic muscle and plays a key role in the homing of EPCs
to ischemic limb. These novel findings suggest that the
modulation of the homing mechanism in the ischemic organ
may be used as a therapeutic strategy to improve the efficacy
of stem cell therapy.
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